The FDA has been busy in 2026. Through the first quarter, the agency has approved 11 novel drugs — a pace that, if sustained, would make 2026 one of the most active years for new drug approvals in recent history. This page tracks every novel drug approval as it happens, with details on what each drug treats, who makes it, and why it matters.
Last updated: April 9, 2026. Bookmark this page — we update it within 48 hours of each new FDA approval.
Complete 2026 FDA Novel Drug Approvals
| Drug Name | Generic Name | Approval Date | Manufacturer | Indication | Category |
|---|---|---|---|---|---|
| Zycubo | zanidatamab | Jan 14, 2026 | Jazz Pharmaceuticals | Biliary tract cancer (BTC) | Oncology |
| Adquey | difamilast | Feb 12, 2026 | Japan Tobacco / Torii Pharmaceutical | Atopic dermatitis (eczema) | Dermatology |
| Bysanti | milsaperidone | Feb 20, 2026 | Sumitomo Pharma | Schizophrenia & Bipolar I disorder | Psychiatry |
| Loargys | pegzilarginase | Feb 20, 2026 | Aeglea BioTherapeutics | Arginase 1 deficiency | Rare Disease |
| Yuviwel | oral semaglutide | Feb 25, 2026 | Novo Nordisk | Chronic weight management | Endocrinology |
| Lynavoy | oral semaglutide | Feb 25, 2026 | Novo Nordisk | Type 2 diabetes mellitus | Endocrinology |
| Icotyde | icotrokinra | Mar 17, 2026 | J&J / Protagonist Therapeutics | Plaque psoriasis | Dermatology |
| Avlayah | avacincaptad pegol | Mar 18, 2026 | Iveric Bio / Astellas Pharma | Geographic atrophy (GA) | Ophthalmology |
| Lifyorli | givinostat | Mar 20, 2026 | Italfarmaco | Duchenne muscular dystrophy (DMD) | Rare Disease |
| Awiqli | insulin icodec | Mar 26, 2026 | Novo Nordisk | Type 2 diabetes mellitus | Endocrinology |
| Foundayo | orforglipron | Mar 31, 2026 | Eli Lilly | Chronic weight management & Type 2 diabetes | Endocrinology |
January 2026 Approvals
Zycubo (zanidatamab) — January 14, 2026
Manufacturer: Jazz Pharmaceuticals
Indication: Treatment of adults with previously treated, unresectable locally advanced or metastatic HER2-positive biliary tract cancer (BTC).
Zycubo is a bispecific HER2-directed antibody that binds two non-overlapping epitopes on the HER2 receptor, triggering potent receptor clustering and internalization. Biliary tract cancers are aggressive and notoriously difficult to treat, and HER2 positivity occurs in roughly 15–20% of cases. In the HERIZON-BTC-01 trial, zanidatamab demonstrated an objective response rate of approximately 41% in pretreated patients, earning it a priority review. This approval provides a meaningful new option for a cancer type with limited targeted therapies.
February 2026 Approvals
Adquey (difamilast) — February 12, 2026
Manufacturer: Japan Tobacco / Torii Pharmaceutical
Indication: Topical treatment of mild-to-moderate atopic dermatitis in patients aged 2 years and older.
Adquey is a topical phosphodiesterase 4 (PDE4) inhibitor that reduces inflammatory signaling in the skin. It joins the growing list of non-steroidal topical options for eczema, alongside crisaborole (Eucrisa), tapinarof (Vtama), and roflumilast (Zoryve). In clinical trials, difamilast demonstrated statistically significant improvements in eczema severity scores with a favorable tolerability profile. It is applied twice daily and has been available in Japan since 2021 under the brand name Moizerto. Read our full Adquey guide.
Bysanti (milsaperidone) — February 20, 2026
Manufacturer: Sumitomo Pharma
Indication: Treatment of schizophrenia in adults and manic or mixed episodes of bipolar I disorder in adults.
Bysanti is an atypical antipsychotic with a novel receptor-binding profile that targets serotonin 5-HT2A and dopamine D2 receptors with improved selectivity designed to reduce metabolic and movement-related side effects. In Phase 3 trials, milsaperidone demonstrated significant reductions in PANSS scores for schizophrenia and YMRS scores for bipolar mania, with a lower incidence of weight gain compared to olanzapine. Read our full Bysanti guide.
Loargys (pegzilarginase) — February 20, 2026
Manufacturer: Aeglea BioTherapeutics
Indication: Treatment of arginase 1 (ARG1) deficiency in adults and pediatric patients aged 2 years and older.
Loargys is the first FDA-approved treatment specifically for arginase 1 deficiency, an ultra-rare urea cycle disorder affecting an estimated 200–300 patients in the United States. The enzyme replacement therapy reduces plasma arginine levels, which, when elevated, cause progressive neurological damage including spasticity, seizures, and cognitive decline. In the pivotal trial, pegzilarginase reduced mean plasma arginine levels by approximately 75% compared to individualized disease management alone.
Yuviwel (oral semaglutide) — February 25, 2026
Manufacturer: Novo Nordisk
Indication: Chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.
Yuviwel is oral semaglutide reformulated and branded specifically for weight management. It is the pill version of Wegovy (injectable semaglutide for weight loss), reaching higher oral doses through the OASIS clinical trial program. In trials, oral semaglutide 50 mg demonstrated approximately 15–17% body weight reduction in completers — narrowing the gap between oral and injectable GLP-1 efficacy. Yuviwel is taken once daily and requires the same fasting protocol as Rybelsus.
Lynavoy (oral semaglutide) — February 25, 2026
Manufacturer: Novo Nordisk
Indication: Type 2 diabetes mellitus as an adjunct to diet and exercise.
Lynavoy is the companion oral semaglutide approval for type 2 diabetes, approved on the same day as Yuviwel. It replaces Rybelsus at higher doses with an improved oral formulation. Like Yuviwel, Lynavoy uses the SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) absorption enhancer technology to facilitate oral bioavailability of the semaglutide peptide.
March 2026 Approvals
Icotyde (icotrokinra) — March 17, 2026
Manufacturer: Johnson & Johnson / Protagonist Therapeutics
Indication: Moderate-to-severe plaque psoriasis in adults and pediatric patients aged 12 and older.
ICOTYDE is the first oral biologic for psoriasis — an oral IL-23 receptor antagonist peptide that achieves biologic-level efficacy without injections. In the VIVID Phase 3 program, 65% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16. This is a landmark approval for psoriasis patients who have refused or avoided injectable biologics. Read our full ICOTYDE guide.
Avlayah (avacincaptad pegol) — March 18, 2026
Manufacturer: Iveric Bio / Astellas Pharma
Indication: Geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
Avlayah is a complement C5 inhibitor administered as an intravitreal injection to slow the progression of geographic atrophy, a leading cause of irreversible vision loss in older adults. It joins Syfovre (pegcetacoplan) as only the second FDA-approved therapy for GA. In the GATHER trials, avacincaptad pegol reduced the rate of GA lesion growth by approximately 35% over 12 months compared to sham injections.
Lifyorli (givinostat) — March 20, 2026
Manufacturer: Italfarmaco
Indication: Duchenne muscular dystrophy (DMD) in patients aged 6 years and older.
Lifyorli is a histone deacetylase (HDAC) inhibitor that targets the fibrotic and inflammatory processes underlying DMD progression. It is the first non-gene therapy disease-modifying treatment for DMD that works regardless of the specific dystrophin mutation. In the EPIDYS trial, givinostat demonstrated significant preservation of upper limb function compared to placebo over 18 months, filling a critical gap for DMD patients who are not candidates for exon-skipping therapies.
Awiqli (insulin icodec) — March 26, 2026
Manufacturer: Novo Nordisk
Indication: Type 2 diabetes mellitus.
Awiqli is the first once-weekly basal insulin, reducing injections from 365 to 52 per year. Based on the ONWARDS trial program, insulin icodec demonstrated non-inferior to superior HbA1c reduction compared to daily insulin glargine. Read our full Awiqli guide.
Foundayo (orforglipron) — March 31, 2026
Manufacturer: Eli Lilly
Indication: Chronic weight management and type 2 diabetes mellitus.
Foundayo is the first non-peptide oral GLP-1 receptor agonist. Unlike Rybelsus, Yuviwel, and Lynavoy (all oral semaglutide peptides requiring fasting), orforglipron is a small molecule that can be taken with or without food. In the ATTAIN Phase 3 program, Foundayo demonstrated approximately 10–12% body weight loss, making it the most convenient oral GLP-1 option available. Eli Lilly has priced it competitively starting at $149/month.
2026 Approval Trends
Several themes stand out from the first quarter of 2026 approvals:
- Oral formulations are winning: Three of the 11 approvals (ICOTYDE, Yuviwel/Lynavoy, Foundayo) represent oral alternatives to previously injectable-only drug classes. The industry is clearly responding to patient demand for pills over needles.
- Endocrinology dominance: Four approvals target diabetes or obesity, reflecting the massive market opportunity and pipeline investment in metabolic diseases.
- Rare diseases getting attention: Two approvals (Loargys, Lifyorli) address ultra-rare conditions with limited prior options, continuing the FDA's priority review pathway for rare disease therapies.
- Dermatology innovation: Two approvals (Adquey, ICOTYDE) bring new options to eczema and psoriasis, both of which affect millions of Americans.
What's Coming Next in 2026?
The second and third quarters of 2026 are packed with high-profile PDUFA dates, including potential decisions on CagriSema (Novo Nordisk's dual GLP-1/amylin for obesity), survodutide, retatrutide, and several other candidates. See our full PDUFA tracker for 2026.
Bookmark this page and check back regularly — we update within 48 hours of every new FDA novel drug approval.
Sources
- FDA Novel Drug Approvals database, 2026.
- Individual drug manufacturer press releases and prescribing information.
- ClinicalTrials.gov results for referenced pivotal trials.
- MedSwitcher editorial research and analysis, April 2026.